Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$133.73
+1.7%
$117.16
$9.95
$148.83
$11.66B0.871.57 million shs447,863 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$228.34
+3.0%
$238.45
$96.09
$260.19
$11.74B0.6774,008 shs431,418 shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$24.05
+2.6%
$19.92
$8.88
$25.00
$3.97B1.062.01 million shs523,609 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$25.45
+1.2%
$23.70
$13.39
$27.72
$12.71B1.685.29 million shs1.46 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-3.77%-3.29%+32.63%+18.01%+1,221.61%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-3.63%-2.91%-11.52%+21.13%+98.42%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-1.22%-0.80%+18.43%+22.07%+159.98%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.58%+0.20%+3.99%+11.16%+70.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$133.73
+1.7%
$117.16
$9.95
$148.83
$11.66B0.871.57 million shs447,863 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$228.34
+3.0%
$238.45
$96.09
$260.19
$11.74B0.6774,008 shs431,418 shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$24.05
+2.6%
$19.92
$8.88
$25.00
$3.97B1.062.01 million shs523,609 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$25.45
+1.2%
$23.70
$13.39
$27.72
$12.71B1.685.29 million shs1.46 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-3.77%-3.29%+32.63%+18.01%+1,221.61%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-3.63%-2.91%-11.52%+21.13%+98.42%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-1.22%-0.80%+18.43%+22.07%+159.98%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.58%+0.20%+3.99%+11.16%+70.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.81
Moderate Buy$148.5411.08% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.95
Moderate Buy$261.4814.51% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.86
Moderate Buy$34.1742.06% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.5512.18% Upside

Current Analyst Ratings Breakdown

Latest DYN, ELAN, ABVX, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/20/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Initiated CoverageOutperform$310.00
7/17/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingSell (D-)
7/17/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingSell (D-)
7/17/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Reiterated RatingSell (D-)
7/15/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$290.00
7/9/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Boost Price TargetOverweight$165.00 ➝ $175.00
7/8/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$290.00
7/7/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$302.00 ➝ $304.00
7/2/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Boost Price TargetBuy$135.00 ➝ $155.00
7/1/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingMarket Outperform$187.00
6/30/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingBuy
(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M18.40N/AN/A$1.75 per share130.48
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.81 per shareN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.70$2.29 per share11.13$13.18 per share1.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%9/14/2026 (Estimated)
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.73N/A56.24N/A-26.59%-267.16%-28.53%8/10/2026 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.22N/AN/AN/AN/A-58.28%-46.77%7/27/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A20.521.69-4.95%7.42%3.66%8/5/2026 (Estimated)

Latest DYN, ELAN, ABVX, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.8919N/AN/AN/A$221.21 millionN/A
8/5/2026Q2 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.27N/AN/AN/A$1.31 billionN/A
7/27/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.74N/AN/AN/AN/AN/A
5/22/2026Q1 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million
5/11/2026Q1 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7723-$0.73+$0.0423-$0.73N/AN/A
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
8.25
8.25
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.32
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.17
19.92
19.92
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6187.16 millionN/ANot Optionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.86 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100165.31 million149.68 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abivax stock logo

Abivax NASDAQ:ABVX

$133.72 +2.23 (+1.69%)
As of 01:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$228.34 +6.70 (+3.02%)
As of 01:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$24.05 +0.60 (+2.56%)
As of 01:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$25.44 +0.31 (+1.21%)
As of 01:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.